Developer docs
API playgroundTry for free, no card

Search company profiles

Syngoi Technologies

Full company profile

uuid000hktc

Namestring
Syngoi Technologies
Legal namestring
SYNGOI TECHNOLOGIES S.L.
Websiteurl
syngoi.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Syngoi Technologies S.L. is a Spanish biotechnology CDMO founded in 2021 by Columbus Venture Partners in Zamudio (Bizkaia), Spain, focused on manufacturing optimized linear synthetic DNA (oDNA) for advanced cell and gene therapies. The company operates a proprietary cell-free enzymatic cGMP platform that produces double-stranded closed linear DNA customized through a library of natural and non-natural nucleotide adaptors, allowing modulation of DNA properties such as stability, immunogenicity, vector release, and nuclear translocation. Service offerings span feasibility, preclinical, clinical-GMP manufacturing, sterile fill & finish, and dedicated project management supported by SAP HANA-based traceability; current facility footprint is 2,500 m² with four cGMP suites, expandable to 4,000 m² and 12 suites.

The business serves biotech and pharmaceutical companies developing mRNA and DNA vaccines, CAR-T cell therapies, gene-editing programs, and viral and non-viral gene therapies, with roughly 90% of customers located in Europe and the United States and capacity for over 25 concurrent projects at kilograms scale post-Series B. Syngoi monetizes via project-based, quote-driven CDMO contracts ranging from R&D/preclinical work through commercial launch support. Active R&D programs include SYNODNA (modular DNA structures), ADNOVA (DNA for AAV manufacturing), and SYNENZYM (engineered Phi29 polymerase), several co-funded by the Basque Government and FEDER. In January 2026 Syngoi was acquired by U.S.-based Artis BioSolutions, retaining its Bilbao industrial base while extending the enzymatic platform to Boston via Artis's Landmark Bio facility in March 2026. Syngoi holds granted patents on its cell-free DNA production method and on oDNA constructs.

Short descriptiontext

Syngoi Technologies is a Spanish biotech CDMO founded in 2021 that manufactures proprietary cell-free enzymatic synthetic DNA (oDNA) under cGMP for biotech and pharma developing gene therapies, mRNA vaccines, and cell therapies.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZamudio, Spain
HQ citystring
Zamudio
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic DNA manufacturing, cell and gene therapy, CDMO services, mRNA vaccine production, enzymatic DNA synthesis
Industry3 codes
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1CDMO Manufacturing Services
TypeOne Time License
Description

Contract Development and Manufacturing Organization providing synthetic DNA production services to biotech and pharmaceutical companies. Services span from R&D and preclinical stages through clinical GMP manufacturing and commercial launch support.

syngoi.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Syngoi Technologies is a Contract Development and Manufacturing Organization (CDMO) that produces optimized linear synthetic DNA (oDNA) using a proprietary cell-free enzymatic cGMP process. The company supplies biotech and pharmaceutical clients with high-purity synthetic double-stranded linear closed DNA customized through proprietary adaptor sequences, supporting applications including mRNA vaccines, CAR-T cell therapy, gene editing, and viral and non-viral gene therapies. Services span R&D and preclinical stages through clinical GMP manufacturing and commercial launch support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • DNA production in weeks instead of months (compared to traditional pDNA production)
+3 more records
Product overview1 text field

Syngoi Technologies is a CDMO (Contract Development and Manufacturing Organization) specializing in synthetic DNA manufacturing for advanced cell and gene therapies. The company's core offering is its proprietary Optimized Linear Synthetic DNA (oDNA) product, a cell-free enzymatic cGMP-manufactured synthetic DNA platform. The technology portfolio includes closed linear DNA, open linear double-stranded, and open linear single-stranded DNA formats, each customized with Syngoi's proprietary adaptor library to optimize properties such as stability, immunogenic response, release from delivery vectors, and nuclear translocation. Adjacent offerings include R&D projects (SYNODNA, ADNOVA, SYNENZYM) for novel DNA structures and enzyme engineering, full cGMP manufacturing services with sterile fill & finish capabilities, HPLC analytical method development, and dedicated project management support.

Product and service1 record
1Optimized Linear Synthetic DNA (oDNA)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-14
Description

Artis BioSolutions (San Diego-based advanced therapies company) completed acquisition of Syngoi Technologies from Columbus Venture Partners and Buenavista Equity Partners in January 2026. Syngoi maintains and expands its scientific and industrial base in Bilbao, Spain while Artis establishes U.S. presence through its Landmark Bio facility in Watertown, MA using Syngoi's enzymatic DNA platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-10
Description

Strategic collaboration to advance gene therapies through development and manufacture at gram scale of clinically and commercially ready synthetic DNA. Combines Syngoi's manufacturing capabilities with Ribbon Bio's algorithm-driven DNA synthesis technology to produce pristine synthetic DNA molecules for next-generation gene therapies.

3Afrigen / CEPI
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-09-09
Description

CEPI funded project ($2.05 million) with Afrigen exploring synthetic DNA as an alternative to traditional plasmid DNA for accelerating mRNA vaccine development, potentially reducing development times by up to 3 times. Syngoi's technology enables 10-day production of synthetic DNA.

syngoi.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.K.-based synthetic DNA manufacturer using an enzymatic, cell-free approach to produce doggybone DNA (dbDNA) for gene therapy and DNA vaccines — the most direct technology competitor to Syngoi's enzymatic oDNA platform, serving overlapping advanced-therapy customers.

TypeBroad incumbent
Description

U.S.-based (now part of Danaher) CDMO and the dominant plasmid DNA supplier for gene therapy and vaccine developers globally; competes with Syngoi on starting-material supply though using bacterial fermentation rather than enzymatic production.

TypeBroad incumbent
Description

Large global CRO/CDMO offering plasmid DNA, viral vector, and cell therapy manufacturing services; competes with Syngoi in the cell and gene therapy CDMO segment with broader portfolio scale.

TypeBroad incumbent
Description

Global CDMO with biologics, cell therapy, and gene therapy manufacturing services (now part of Novo Holdings); competes with Syngoi for advanced-therapy manufacturing engagements, particularly around viral vector and cell therapy supply chains.

TypeBroad incumbent
Description

Global CDMO offering cell and gene therapy, viral vector, and biopharmaceutical manufacturing services; overlaps with Syngoi in serving gene therapy developers requiring GMP-grade DNA and vector supply.

TypeDirect peer
Description

U.S.-based viral vector and gene therapy CDMO offering GMP-grade lentiviral, AAV, and cell processing services; comparable as a focused advanced-therapy CDMO serving similar biotech and pharma customers, though specialized in vectors rather than DNA.

TypeDirect peer
Description

U.S.-based contract manufacturer specializing in plasmid DNA for gene therapy, DNA vaccines, and cell therapy applications; direct competitor in GMP-grade DNA supply with established customer base.

8DNA Script
TypeEmerging player
Description

French/U.S. enzymatic DNA synthesis technology company developing enzymatic oligonucleotide synthesis; an emerging alternative DNA-writing technology with potential overlap to Syngoi's enzymatic approach for therapeutic DNA applications.

TypeEmerging player
Description

U.S.-based DNA synthesis company providing synthetic DNA, including clonal genes and DNA fragments, with growing capabilities in DNA data storage and biologic discovery; competes in synthetic DNA supply with a silicon-based platform, partially overlapping Syngoi's customer base.

10Cobra Biologics (Charles River)
TypeBroad incumbent
Description

U.K./Sweden-based plasmid DNA, viral vector, and cell therapy CDMO (now part of Charles River); competes with Syngoi in plasmid DNA and gene therapy manufacturing services for European biotech customers.

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syngoi Technologies

Biopharmaceutical CDMO Servicessyngoi.com

Syngoi Technologies is a Spanish biotech CDMO founded in 2021 that manufactures proprietary cell-free enzymatic synthetic DNA (oDNA) under cGMP for biotech and pharma developing gene therapies, mRNA vaccines, and cell therapies.

What Syngoi Technologies does

Syngoi Technologies S.L. is a Spanish biotechnology CDMO founded in 2021 by Columbus Venture Partners in Zamudio (Bizkaia), Spain, focused on manufacturing optimized linear synthetic DNA (oDNA) for advanced cell and gene therapies. The company operates a proprietary cell-free enzymatic cGMP platform that produces double-stranded closed linear DNA customized through a library of natural and non-natural nucleotide adaptors, allowing modulation of DNA properties such as stability, immunogenicity, vector release, and nuclear translocation. Service offerings span feasibility, preclinical, clinical-GMP manufacturing, sterile fill & finish, and dedicated project management supported by SAP HANA-based traceability; current facility footprint is 2,500 m² with four cGMP suites, expandable to 4,000 m² and 12 suites.

The business serves biotech and pharmaceutical companies developing mRNA and DNA vaccines, CAR-T cell therapies, gene-editing programs, and viral and non-viral gene therapies, with roughly 90% of customers located in Europe and the United States and capacity for over 25 concurrent projects at kilograms scale post-Series B. Syngoi monetizes via project-based, quote-driven CDMO contracts ranging from R&D/preclinical work through commercial launch support. Active R&D programs include SYNODNA (modular DNA structures), ADNOVA (DNA for AAV manufacturing), and SYNENZYM (engineered Phi29 polymerase), several co-funded by the Basque Government and FEDER. In January 2026 Syngoi was acquired by U.S.-based Artis BioSolutions, retaining its Bilbao industrial base while extending the enzymatic platform to Boston via Artis's Landmark Bio facility in March 2026. Syngoi holds granted patents on its cell-free DNA production method and on oDNA constructs.

Syngoi Technologies firmographics

Firmographics
Name
Syngoi Technologies
Legal name
SYNGOI TECHNOLOGIES S.L.
Website
https://syngoi.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
11–50 employees
Short description
Syngoi Technologies is a Spanish biotech CDMO founded in 2021 that manufactures proprietary cell-free enzymatic synthetic DNA (oDNA) under cGMP for biotech and pharma developing gene therapies, mRNA vaccines, and cell therapies.
Ownership category
akta.pro rank

Syngoi Technologies industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Synthetic DNA manufacturing
  • Cell and gene therapy
  • CDMO services
  • MRNA vaccine production
  • Enzymatic DNA synthesis

Where Syngoi Technologies is headquartered

Location

Headquarters

HQ city
Zamudio
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Syngoi Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. CDMO Manufacturing Services: Contract Development and Manufacturing Organization providing synthetic DNA production services to biotech and pharmaceutical companies. Services span from R&D and preclinical stages through clinical GMP manufacturing and commercial launch support.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Syngoi Technologies product offering

Product offering

Core offering

Syngoi Technologies is a Contract Development and Manufacturing Organization (CDMO) that produces optimized linear synthetic DNA (oDNA) using a proprietary cell-free enzymatic cGMP process. The company supplies biotech and pharmaceutical clients with high-purity synthetic double-stranded linear closed DNA customized through proprietary adaptor sequences, supporting applications including mRNA vaccines, CAR-T cell therapy, gene editing, and viral and non-viral gene therapies. Services span R&D and preclinical stages through clinical GMP manufacturing and commercial launch support.

Product overview

Syngoi Technologies is a CDMO (Contract Development and Manufacturing Organization) specializing in synthetic DNA manufacturing for advanced cell and gene therapies. The company's core offering is its proprietary Optimized Linear Synthetic DNA (oDNA) product, a cell-free enzymatic cGMP-manufactured synthetic DNA platform. The technology portfolio includes closed linear DNA, open linear double-stranded, and open linear single-stranded DNA formats, each customized with Syngoi's proprietary adaptor library to optimize properties such as stability, immunogenic response, release from delivery vectors, and nuclear translocation. Adjacent offerings include R&D projects (SYNODNA, ADNOVA, SYNENZYM) for novel DNA structures and enzyme engineering, full cGMP manufacturing services with sterile fill & finish capabilities, HPLC analytical method development, and dedicated project management support.

Differentiator

Problem solved

Functional benefit

Products and services

  • Optimized Linear Synthetic DNA (oDNA)

Quantifiable outcome

  • DNA production in weeks instead of months (compared to traditional pDNA production)
  • +3 more outcomes

Companies that use Syngoi Technologies

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Syngoi Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Syngoi Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Artis BioSolutionscoreStrategic or Co-development Partner · 14 January 2026Artis BioSolutions (San Diego-based advanced therapies company) completed acquisition of Syngoi Technologies from Columbus Venture Partners and Buenavista Equity Partners in January 2026. Syngoi maintains and expands its scientific and industrial base in Bilbao, Spain while Artis establishes U.S. presence through its Landmark Bio facility in Watertown, MA using Syngoi's enzymatic DNA platform.
  • Ribbon BiocoreStrategic or Co-development Partner · 10 March 2025Strategic collaboration to advance gene therapies through development and manufacture at gram scale of clinically and commercially ready synthetic DNA. Combines Syngoi's manufacturing capabilities with Ribbon Bio's algorithm-driven DNA synthesis technology to produce pristine synthetic DNA molecules for next-generation gene therapies.
  • Afrigen / CEPIminorStrategic or Co-development Partner · 9 September 2024CEPI funded project ($2.05 million) with Afrigen exploring synthetic DNA as an alternative to traditional plasmid DNA for accelerating mRNA vaccine development, potentially reducing development times by up to 3 times. Syngoi's technology enables 10-day production of synthetic DNA.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Syngoi Technologies competitors and assessment

Company assessment

Direct peers

  • Touchlight Genetics: U.K.-based synthetic DNA manufacturer using an enzymatic, cell-free approach to produce doggybone DNA (dbDNA) for gene therapy and DNA vaccines — the most direct technology competitor to Syngoi's enzymatic oDNA platform, serving overlapping advanced-therapy customers.
  • Genezen: U.S.-based viral vector and gene therapy CDMO offering GMP-grade lentiviral, AAV, and cell processing services; comparable as a focused advanced-therapy CDMO serving similar biotech and pharma customers, though specialized in vectors rather than DNA.
  • VGXI (Genezen/pregenex): U.S.-based contract manufacturer specializing in plasmid DNA for gene therapy, DNA vaccines, and cell therapy applications; direct competitor in GMP-grade DNA supply with established customer base.

Broad incumbents

  • Aldevron: U.S.-based (now part of Danaher) CDMO and the dominant plasmid DNA supplier for gene therapy and vaccine developers globally; competes with Syngoi on starting-material supply though using bacterial fermentation rather than enzymatic production.
  • Charles River Laboratories: Large global CRO/CDMO offering plasmid DNA, viral vector, and cell therapy manufacturing services; competes with Syngoi in the cell and gene therapy CDMO segment with broader portfolio scale.
  • Catalent: Global CDMO with biologics, cell therapy, and gene therapy manufacturing services (now part of Novo Holdings); competes with Syngoi for advanced-therapy manufacturing engagements, particularly around viral vector and cell therapy supply chains.
  • AGC Biologics: Global CDMO offering cell and gene therapy, viral vector, and biopharmaceutical manufacturing services; overlaps with Syngoi in serving gene therapy developers requiring GMP-grade DNA and vector supply.
  • Cobra Biologics (Charles River): U.K./Sweden-based plasmid DNA, viral vector, and cell therapy CDMO (now part of Charles River); competes with Syngoi in plasmid DNA and gene therapy manufacturing services for European biotech customers.

Emerging players

  • DNA Script: French/U.S. enzymatic DNA synthesis technology company developing enzymatic oligonucleotide synthesis; an emerging alternative DNA-writing technology with potential overlap to Syngoi's enzymatic approach for therapeutic DNA applications.
  • Twist Bioscience: U.S.-based DNA synthesis company providing synthetic DNA, including clonal genes and DNA fragments, with growing capabilities in DNA data storage and biologic discovery; competes in synthetic DNA supply with a silicon-based platform, partially overlapping Syngoi's customer base.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Syngoi Technologies social profiles

Digital presence

Syngoi Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syngoi Technologies leadership team

Management profile

Number of profiles

Profiles3 records

Syngoi Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syngoi Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syngoi Technologies

What does Syngoi Technologies do?

Syngoi Technologies is a Contract Development and Manufacturing Organization (CDMO) that produces optimized linear synthetic DNA (oDNA) using a proprietary cell-free enzymatic cGMP process. The company supplies biotech and pharmaceutical clients with high-purity synthetic double-stranded linear closed DNA customized through proprietary adaptor sequences, supporting applications including mRNA vaccines, CAR-T cell therapy, gene editing, and viral and non-viral gene therapies. Services span R&D and preclinical stages through clinical GMP manufacturing and commercial launch support.

Is Syngoi Technologies a public or private company?

Syngoi Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Syngoi Technologies founded?

Syngoi Technologies was founded in 2021. It employs 11 to 50 people.

Where is Syngoi Technologies based?

Syngoi Technologies is headquartered in Zamudio, Spain, in the Europe region.

How does Syngoi Technologies make money?

One revenue line is on record: CDMO Manufacturing Services.

Who are Syngoi Technologies's main competitors?

Direct peers on record are Touchlight Genetics, Genezen and VGXI (Genezen/pregenex). Broad incumbents are Aldevron, Charles River Laboratories, Catalent, AGC Biologics and Cobra Biologics (Charles River). Emerging players are DNA Script and Twist Bioscience.

Does Syngoi Technologies have an API?

No public API is recorded for Syngoi Technologies.

What industry is Syngoi Technologies in?

Syngoi Technologies's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream), with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageLandmark Bio and Syngoi Technologies to Operate as Artis BioSolutions, an End-to-end Gene-to-GMP Platform for Genetic MedicinesArtis BioSolutions announced that Landmark Bio (Watertown, Massachusetts) and Syngoi (Bilbao, Spain) will now operate under a unified Artis BioSolutions brand, completing a transatlantic platform that connects synthetic DNA production with downstream development and GMP manufacturing for genetic medicines. The company, which secured a $18.3 million award from ARPA-H in April for the TRANSFORM EV project on scalable continuous manufacturing for extracellular vesicle therapies, is positioning itself as a single integrated alternative to fragmented supply chains in the advanced therapy industry. Artis BioSolutions is based in San Diego and operates production sites in both the United States and Spain.InvestorsinhealthcareSpain: Artis BioSolutions acquires CDMO Syngoi TechnologiesUS-based biotech Artis BioSolutions has acquired Spain-based CDMO Syngoi Technologies from private equity firm Buenavista Equity Partners and venture capital firm Columbus Venture Partners. Syngoi Technologies, formed in 2021, has developed a synthetic DNA platform based on enzymatic processes designed to address production bottlenecks in the gene and cell therapy industry. The acquisition will enable Syngoi to achieve industrial scale, operational robustness, and global reach as part of Artis BioSolutions' ecosystem.Empresas de Capital Riesgo en EspaColumbus Venture Partners successfully completes the sale of Syngoi Technologies to U.S. based Artis BioSolutionsColumbus Venture Partners has completed the sale of Syngoi Technologies, a biotechnology CDMO it originated and developed, to U.S.-based Artis BioSolutions, a leading international platform for advanced therapies development and manufacturing. Syngoi Technologies, founded in the Basque Country in 2021, has developed an enzymatic synthetic DNA platform addressing key supply chain challenges in gene and cell therapy manufacturing. The transaction validates Columbus Venture Partners' model of creating strategic bioindustrial infrastructure from differentiated science and integrating it into global platforms, while preserving Syngoi's scientific and industrial base in Bilbao, Spain.Pulse 2.0Artis BioSolutions To Acquire Syngoi TechnologiesArtis BioSolutions signed a definitive agreement to acquire Syngoi Technologies, a Spanish biotech developing enzymatic synthetic DNA manufacturing. The deal aims to add faster, lower-cost synthetic DNA production to Artis' gene-to-drug platform, with a U.S. operating presence planned through Landmark Bio. Closing is expected in Q1 2026, subject to regulatory approvals.SdbnArtis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology – San Diego Biotechnology NetworkArtis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, has entered into a definitive agreement to acquire Syngoi Technologies, a Spanish biotechnology company pioneering enzymatic approaches for synthetic DNA manufacturing. The acquisition will integrate Syngoi's GMP-ready facilities in Bilbao, Spain with Artis' existing U.S. platform through its wholly-owned entity Landmark Bio, creating a combined offering for advanced-therapy developers globally. The transaction is expected to close in Q1 2026, subject to customary regulatory approvals and closing conditions.Business Wire BlogArtis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA TechnologyArtis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, has entered into a definitive agreement to acquire Syngoi Technologies, a Spanish biotechnology company pioneering enzymatic approaches for synthetic DNA manufacturing. The acquisition will integrate Syngoi's GMP-ready facilities in Bilbao, Spain into Artis' global footprint, establishing the company as one of the first platforms to combine GMP synthetic DNA manufacturing with integrated advanced-therapy capabilities in the United States. The transaction is expected to close in Q1 2026, subject to customary regulatory approvals and closing conditions, with financial terms not disclosed.The Pharma LetterArtis BioSolutions to acquire Syngoi TechnologiesArtis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company that launched in April, has entered into a definitive agreement to acquire Syngoi Technologies, a Spanish biotechnology company. Syngoi Technologies specializes in novel enzymatic approaches for manufacturing synthetic DNA technologies. This acquisition would expand Artis BioSolutions' capabilities in the synthetic DNA manufacturing space.